Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
16 participants
INTERVENTIONAL
2014-09-30
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache
NCT03422796
The Headache Inducing Effects of Cilostazol on Migraine Patients
NCT01841827
Induction of Migraine Aura With Sildenafil
NCT02795351
The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache
NCT02486276
Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache
NCT05595993
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
Cilostazol 200 mg single dose
Cilostazol
Single oral administration of active or placebo one week apart
Placebo
Placebo capsule
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cilostazol
Single oral administration of active or placebo one week apart
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Minimum of 2 attacks/year
Exclusion Criteria
* Cardiac arrhythmias
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Herlev Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christina Kruuse
Associate professor, consultant neurologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christina Kruuse, MD PhD DMSc
Role: PRINCIPAL_INVESTIGATOR
Consultant Neurologist, Dept Neurology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Herlev Hospital, Dept Neurology
Herlev, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-004188-29
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
H-3-2013-166
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.